Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maryland for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maryland only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maryland (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Howard Hauptman (NPI 1861461220)

Field	Value
Entity Type	Individual
Organization	Howard Hauptman
Address	1220b E Joppa Rd
City	Baltimore
State	MD
ZIP	21286
Taxonomy	Rheumatology Physician
NPI Enumerated	March 16, 2006

Payer Source	Total Paid
Medicare	$2.9M
Medicaid	$0

Key Findings

This provider’s billing footprint is effectively single‑payer: lifetime Medicare revenue is $2.9M and there is no Medicaid billing on file. The absence of Medicaid activity suggests the practice’s patient mix or contracting strategy is concentrated on Medicare beneficiaries and commercial arrangements rather than state Medicaid programs in Maryland (BALTIMORE, MD).

Revenue is highly concentrated in a handful of biologic infusion drugs: the top three Medicare codes (J9312, J1745, J0129) account for 59.0% of the provider’s total Medicare revenue. Individually those top drivers are J9312 (22.6%), J1745 (21.7%), and J0129 (14.7%), indicating most Medicare dollars flow through high‑cost injectable biologics.

The code mix and volumes indicate an infusion‑center or infusion‑heavy rheumatology practice focused on biologic therapies and supervised parenteral administration. High aggregate claims and revenue for J9312 (10.9K claims, $654.1K), J1745 (24.1K claims, $626.1K), J0129 (12.5K claims, $426K) alongside injectable immunomodulators such as J3262, J1602 and J0717 point to routine in‑office/clinic administration of biologic agents rather than primarily office‑visit management. The presence of chemotherapy administration codes (96413, 96401, 96415) further underscores substantial infusion throughput and nursing/infusion infrastructure.

On competitive standing the provider is a national high‑volume outlier for specific products: J9312 ranks #5 of 317 (99th percentile) and is described as notably above typical national volume, while J1745 ranks #10 of 1352 (99th percentile) and is labeled an extreme outlier. By contrast J0129 sits at a more typical volume level (rank #335 of 1221, 73rd percentile). These rankings imply national prominence for rituximab and infliximab administration but a more ordinary position for abatacept.

High E/M and infusion service volumes reinforce a busy ambulatory infusion practice: 99214 (1.1K claims, $107.1K) and 99213 (954 claims, $65.8K) both rank in the 98th percentile and are called extreme outliers, indicating unusually large office visit throughput for a rheumatology specialty. Infusion administration metrics also stand out — 96413 ranks at the 99th percentile (extreme outlier) and 96415 ranks at the 99th percentile (extreme outlier) — together these support a consistent, high‑volume infusion operation rather than occasional dosing.

The provider’s dependence on a small set of high‑revenue biologic codes creates concentration risk: with the top three codes contributing 59.0% of Medicare revenue, shifts in drug utilization, biosimilar adoption, or reimbursement for those specific HCPCS could materially affect revenue. Analysts should treat changes to access, coverage, or pricing for J9312 and J1745 as high‑impact to this profile.

Tenure data show the NPI was enumerated 2006-03-16 (~20 years ago), indicating a long‑standing presence in the market. That longevity, paired with very high infusion and E/M ranks, suggests an established referral and operational footprint for delivering infused biologic therapies in the Baltimore area.

The complete absence of Medicaid billing on file is a notable market characteristic with operational implications: the practice either does not participate in Medicaid or has minimal Medicaid patient volume, which affects payer contracting leverage and may narrow sensitivity to Medicaid reimbursement pressure while increasing reliance on Medicare and commercial payers.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

36 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9312	Injection, rituximab, 10 mg	10,900	$60	$654.1K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	24,080	$30	$626.1K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	12,530	$30	$426K
J0897	Injection, denosumab, 1 mg	12,600	$20	$226.8K
J3262	Injection, tocilizumab, 1 mg	38,600	$10	$193K
J1602	Injection, golimumab, 1 mg, for intravenous use	18,670	$10	$186.7K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	44,800	$1	$179.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,010	$110	$115.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,080	$100	$107.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	950	$70	$65.8K

Showing 1–10 of 36

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 36 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maryland Distribution

Howard Hauptman — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maryland

Full comparison — all codes billed, vs. state median

36 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	10	40	6,060	$30	$290.2K
J9312	1	10	2,900	$60	$261.2K
J0717	12	30	41,000	$1	$225.7K
J3262	9	20	28,780	$1	$159K
J0897	42	340	3,600	$20	$114.4K
J1745	1	40	2,810	$30	$109K
J1602	3	30	8,300	$10	$102.8K
96413	3	230	200	$110	$29.6K
99214	460	10,270	150	$90	$24.1K
80053	104	430	250	$10	$13.1K

Showing 1–10 of 36

Related Providers

Other providers that share a Tax Identification Number (TIN) with Howard Hauptman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Medstar Medical Group Ii LLC	MD	General Practice Physician	$0	$91.5M
Johns Hopkins University	MD	Emergency Medicine Physician	$0	$21.1M
The Johns Hopkins Hospital	MD	General Acute Care Hospital	$0	$19.9M
Johns Hopkins University	MD	Body Imaging Physician	$0	$15.3M
William Sharfman	MD	Medical Oncology Physician	$9.1M	$0
Johns Hopkins University	MD	Pediatric Emergency Medicine (Pediatrics) Physician	$0	$8.6M
Johns Hopkins University	MD	Internal Medicine Physician	$0	$6.2M
Johns Hopkins University	MD	Cardiovascular Disease Physician	$0	$4.9M
Johns Hopkins University	MD	Hospitalist Physician	$0	$4.5M
Daniel Becker	MD	Neurology Physician	$3.9M	$0

Nearby Providers

Other providers in the same ZIP code as Howard Hauptman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Baltimore County Maryland Office Of Finance	MD	Ambulance	$12.2M	$16.1M
Redesigning Minds, LLC	MD	Community/Behavioral Health Agency	$0	$19.9M
Real Life Changes, LLC	MD	Community/Behavioral Health Agency	$0	$7.2M
Child And Adult Psychiatry Charito Quintero-howard, Md, LLC	MD	Community Health Clinic/Center	$0	$6.4M
Arrow Child & Family Ministries Of Maryland	MD	Community/Behavioral Health Agency	$0	$5.4M
Lifebridge Community Pediatrics, LLC	MD	Pediatrics Physician	$0	$4.9M
Mct, LLC	MD	Land Ambulance	$1.9M	$772.5K
Tazeen Rehman	MD	Rheumatology Physician	$1.6M	$0
Cd Laboratories, Inc.	MD	Clinical Medical Laboratory	$771.3K	$416.7K
Endoscopy Center Of North Baltimore LLC	MD	Ambulatory Surgical Clinic/Center	$854.1K	$0

Howard Hauptman — Billing Profile & Reimbursement Data

Sign up for Howard Hauptman — Billing Profile & Reimbursement Data policy alerts

Howard Hauptman — Billing Profile & Reimbursement Data

Sign up for Howard Hauptman — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References